ClinicalTrials.Veeva

Menu

Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis

T

Tehran University of Medical Sciences

Status and phase

Unknown
Phase 3
Phase 2

Conditions

Mucopolysaccharidosis

Treatments

Procedure: Stem Cell Transplantation
Drug: Conditioning regimen
Drug: Graft-versus-host disease (GVHD) prophylaxis

Study type

Interventional

Funder types

Other

Identifiers

NCT01238328
HORCSCT-0906

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and side effects of donor hematopoietic cells using chemotherapy regimen without total-body irradiation in children undergoing a hematopoietic stem cell transplant for Mucopolysaccharidosis. The blood stem cells will be derived from either related donor or unrelated umbilical cord blood or haploidentical donor.

Enrollment

10 estimated patients

Sex

All

Ages

Under 8 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of Mucopolysaccharidosis type 1, 6 and 7 confirm by leukocyte enzyme assay
  • Age up to 8 year old
  • Have suitable donor

Exclusion criteria

  • Creatinine clearance ≤ 40ml/min/1.73m^2
  • Bilirubin ≥ 3mg/dL
  • SGPT ≥ 500 U/L
  • Current severe infection
  • Evidence of CNS involvement
  • Morbidity such as blindness or deafness

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

10 participants in 1 patient group

Transplantation
Experimental group
Treatment:
Procedure: Stem Cell Transplantation
Drug: Graft-versus-host disease (GVHD) prophylaxis
Drug: Conditioning regimen

Trial contacts and locations

1

Loading...

Central trial contact

Amir Ali Hamidieh, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems